Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 20,129 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Circulatory Disease Clear all

Conditions: Sturge Weber Syndrome, Port-wine Mark
Interventions: Timolol, Preservative free artificial tear gel.; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 2 Years to 10 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV, Hepatitis C
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Volunteers
Interventions: Placebo, MEDI5884 Dose 1, MEDI5884 Dose 2, MEDI5884 Dose 3, MEDI5884 Dose 4; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Glendale, California

Conditions: Multiple Myeloma
Interventions: TBL 12; Drug
Lead sponsor: Jagannath, Sundar, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Stress Disorders, Post-Traumatic
Interventions: Cognitive behavioral therapy (CBT), Educational session and treatment as usual; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: New York, New York • Queens, New York

Conditions: Diabetic Macular Edema
Interventions: Experimental: Group 1 - 50mg RZ402, Experimental: Group 2 - 200mg RZ402, Experimental: Group 3 - 400mg RZ402, Placebo: Group 4 - Placebo; Drug · Other
Lead sponsor: Rezolute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more

Conditions: Heart Failure
Interventions: C-Pulse™ (Implantable Counterpulsation Therapy); Device
Lead sponsor: Nuwellis, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 6
States / cities: Birmingham, Alabama • Louisville, Kentucky • Saint Paul, Minnesota + 3 more

Conditions: Fabry Disease
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 1 Year and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Foot
Interventions: Removable cast walker, Irremovable cast walker; Device
Lead sponsor: University of Arizona; Other
Eligibility: 37 Years to 68 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Cardiac Arrhythmia
Interventions: Electrophysiology procedure; Device
Lead sponsor: CathVision ApS; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Abnormalities, Blood Coagulation Disorder, Brain Disease, Cerebrovascular Accident, Vascular Disease
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Up to 45 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension
Interventions: Hypertension Coaching Application and Home Monitor, Control: Tracking Application and Home Monitor; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Heart Septal Defects, Ventricular, Atrioventricular Septal Defect
Interventions: IV L-carnitine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 2 Months to 12 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Kidney Disease, Cardiovascular Disease
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Uncontrolled Hypertension
Interventions: RHYTHM (Remote Hypertension Tracking Help Management), Enhanced usual care (UC); Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years to 85 Years
Enrollment: 864 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Multiple Myeloma, Immune System Diseases
Interventions: CAR138 T Cells; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2039
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Isolated Aortic Stenosis, Mitral Regurgitation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Home hospital care; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Asthma, Atherosclerosis, Metabolic Syndrome, Insulin Resistance, Cancer
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 725 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Heart Failure
Interventions: Non-Invasive Continuous Remote Patient Monitoring, Affective Analysis of Participant Response to Continuous Remote Patient Monitoring; Device · Other
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Amnesia, Dementia, Healthy, Nervous System Disease
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 830 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1992 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hemophilia A, Bleeding Disorder
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 10 Years to 65 Years · Female only
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation, Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8; Procedure · Drug · Radiation
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cardiac Catheterization, Blood Pressure, Heart Ventricles, Echocardiography, Heart Failure
Interventions: Definity; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 21 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects

Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884

Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma

Safety and Efficacy of Cognitive Behavior Therapy for People With Post-traumatic Stress and Cardiovascular Illness

Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)

C-Pulse IDE Feasibility Study- A Heart Assist System

Evaluation of Phenotypic Variability in Fabry Disease

The Association Between Unprotected Standing, Walking and Wound Healing in Diabetes

An Evaluation of the Safety and Performance of the CathVision ECGenius® System.

Study of Abnormal Blood Clotting in Children With Stroke

The Smart Hypertension Control Study

Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow

Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation

Remote Hypertension Management for Black Patients

Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

A Study to Evaluate a Computerized Stethoscope Called ©Voqx to Diagnose Heart Disease

Rural Home Hospital: Proof of Concept

Study of the Effect of Innate on the Inflammatory Response to Endotoxin

The CASCADE HF Soft Launch and Calibration Phase I and II

Magnetic Resonance Imaging for the Study of Patients With Neurological Disorders

Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

Noninvasive, Subharmonic Intra-Cardiac Pressure Measurement